Breast Cancer Clinical Trials in Burlington, Massachusetts

7 studies are recruiting for breast cancer in Burlington, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

   This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

   Stage

   Phase 3

   Ages

   18 to 60

   Site

   Lahey Clinic, Burlington, Massachusetts

   Locations

   1261 in total

   Run by

   NRG Oncology

   See if you can join NCT05879926 on ClinicalTrials.gov

2. ATEMPT 2.0: Adjuvant T-DM1 vs TH

   This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Lahey Clinic, Burlington, Massachusetts

   Locations

   53 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04893109 on ClinicalTrials.gov

3. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

   This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinical Trial Site, Burlington, Massachusetts

   Locations

   181 in total

   Run by

   Olema Pharmaceuticals, Inc.

   See if you can join NCT07085767 on ClinicalTrials.gov

4. E-Mindfulness Approaches for Living After Breast Cancer

   NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants wi…

   Stage

   Phase 3

   Ages

   18 to 50

   Site

   Lahey Clinic, Burlington, Massachusetts

   Locations

   383 in total

   Run by

   NRG Oncology

   See if you can join NCT06748222 on ClinicalTrials.gov

5. Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

   This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor [HR]-negative and HR-positive) unresectable and/or metastatic breast cancer.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Beth Israel Lahey Health, Burlington, Massachusetts

   Locations

   88 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT05950945 on ClinicalTrials.gov

6. SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers

   Investigators aim to conduct a type 1 hybrid effectiveness-implementation surgeon-level cluster randomized clinical trial (RCT) of a multi-level intervention, a shared decision making training for surgeons plus patient decision aid vs. usual care (UC), at 7 large health systems across the U.S. to l…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Lahey Hospital and Medical Center, Burlington, Massachusetts

   Locations

   11 in total

   Run by

   Beth Israel Deaconess Medical Center

   See if you can join NCT06896474 on ClinicalTrials.gov

7. EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

   The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Lahey Hospital & Medical Center, Burlington, Massachusetts

   Locations

   58 in total

   Run by

   Exact Sciences Corporation

   See if you can join NCT06401421 on ClinicalTrials.gov